Studies at the Big South/West Node

CTN-0090 MBC4OUD – Lead Investigator (LI), Madkuhar Trivedi, MD; Site PI, Tara Karns-Wright, PhD

This is an observational feasibility project evaluating the impact of universal screening and enhanced access to care for patients with opioid use disorder via development and implementation of a web-based software program that provides clinical decision support to primary care providers for the diagnosis and treatment of opioid use disorder (OUD) with buprenorphine.

CTN-097 SWIFT – Participating Study Site: Nexus Recovery Center in Dallas

The objective of the SWIFT study is to foster adoption of rapid initiation of treatment with extended-release injection naltrexone at inpatient or residential community treatment programs.

CTN-0100 RDD – Participating Study Site: UAMS CAST Clinic in Little Rock, AK

This study is designed to examine multiple outcomes for: retention in treatment for MOUD among patients initiating treatment for OUD, to test strategies to improve outcomes among patients who have achieved stable remission on MOUD and want to discontinue MOUD, and to develop models to predict who is able to discontinue MOUD without relapse, based on participant characteristics, including duration of MOUD prior to discontinuation.

CTN-0108 STIMULUS – LIs: Kathleen Brady, MD, PhD, Southern Consortium Node & Madhukar Trivedi, MD

This feasibility study is designed for participants who currently want to reduce or eliminate their stimulant use disorder. The primary objective of this study is to determine the feasibility of repetitive transcranial magnetic stimulation (rTMS) for individuals with moderate to severe cocaine or methamphetamine use disorder. 4 study sites

CTN-0109 CURB2 – LI: Madhukar Trivedi, MD & Steven Shoptaw, PhD

This is an 8-week, double-blind, randomized placebo-controlled trial to determine the efficacy of a combination of extended-release naltrexone and extended-release buprenorphine compared to matched placebo injections for the treatment of moderate to severe cocaine use disorder. 12 study sites

(Related) CTN-0109A I-DREM – LI, Madhukar Trivedi, MD; Co-LIs, Steven Shoptaw, PhD & Hoa Vo, PhD

Innovative Development of Research Engagement Manual (I-DREM) will map out sustainable solutions that would benefit the recruitment of Black individuals into SUD clinical trials and move the meter towards the goal of making diversity in clinical trials a standard part of the SUD clinical research model. 12 study sites

CTN-0110 MURB – LIs: Steven Shoptaw, PhD & Madhukar Trivedi, MD

This study is a 12-week double-blind, randomized placebo-controlled trial that will investigate the use of injectable buprenorphine compared to injectable placebo for the treatment of moderate to severe methamphetamine use disorder among individuals who also have mild co-use of opioids. 6 study sites

CTN-0120 RMIST – LI: Madhukar Trivedi, MD

This is an observational study to evaluate the performance and acceptability of two different methods of remote methadone ingestion surveillance (RMIST) that may mitigate the patient safety risks of take-home methadone treatment regimens for opioid use disorder while minimizing the risk of diversion. 1 study site

CTN-0132 KMD – LIs: Madhukar Trivedi, MD & Steven Shoptaw, PhD

This pilot study will be a randomized, double-blind, controlled trial comparing twice weekly IV ketamine (0.71mg/kg; dose reduction down to .5mg/kg will be allowed for those not tolerating the target dose) versus IV midazolam (0.025mg/kg) over 52 minutes delivered across 6 weeks in 80 adults with moderate to severe methamphetamine use disorder. 4 study sites